Effectiveness and safety of mexidol forte 250 in the sequential therapy in patients with chronic ischemia

Kataeva N.G.; Zamoshchina T.A.; Svetlik M.V.

doi:https://doi.org/10.17116/jnevro202012011159

Kataeva N.G.

Siberian State Medical University

Zamoshchina T.A.

Siberian State Medical University;
National Research Tomsk State University

Svetlik M.V.

Siberian State Medical University;
National Research Tomsk State University

Effectiveness and safety of mexidol forte 250 in the sequential therapy in patients with chronic ischemia

Authors:

Kataeva N.G., Zamoshchina T.A., Svetlik M.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(11): 59‑63

DOI: 10.17116/jnevro202012011159

Read: 6203 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Kataeva NG, Zamoshchina TA, Svetlik MV. Effectiveness and safety of mexidol forte 250 in the sequential therapy in patients with chronic ischemia. S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(11):59‑63. (In Russ.)
https://doi.org/10.17116/jnevro202012011159

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)

Использование инфографики авторами научных работ

Close metadata

OBJECTIVE

To study of efficacy and safety of mexidol used as intravenous infusion for 14 days, followed by per os treatment with mexidol FORTE 250 for 60 days in patients with chronic brain ischemia (CHM) complicated with arterial hypertension and atherosclerosis.

MATERIAL AND METHODS

The mexidol group included 27 patients (24 women and 3 men) with CHM I—II gr and the combination of arterial hypertension and atherosclerosis who received intravenous infusions of mexidol (500 mg once daily) within 14 days, with the subsequent per os treatment with mexidol FORTE 250 in a daily dose of 750 mg (1 tablet 3 times a day) for 60 days. The comparison group consisted of 30 patients (22 women and 8 men) with CHM I—II gr, comparable in age, nature of risk factors and expression of neurological manifestations. Patients in both groups received basic medications to treat their risk factors. Motor activity (Tinetti test), cognitive functions (MoCa test), anxiety and depression (Hamilton anxiety and depression scale), clinical condition (General Clinical Impression scale) were assessed.

RESULTS AND CONCLUSION

Inclusion of mexidol (500 mg iv infusion once a day within 14 days with the subsequent oral administration of 750 mg (1 tablet 3 times a day) for 60 days) in standard therapy of arterial hypertension with atherosclerosis and chronic brain ischemia is expedient. The results show greater clinical efficacy and sufficient safety of such combination therapy. By the end of therapy (day 74), patients in the mexidol group have a reliable improvement in motor activity, cognitive function and psychoemotional sphere, as well as a decrease in fatigue and neurological manifestations compared with the comparison group.

Keywords:

chronic ischemia of a brain

mexidol

mexidol FORTE 250

Authors:

Kataeva N.G.

Siberian State Medical University

Zamoshchina T.A.

Siberian State Medical University;
National Research Tomsk State University

Svetlik M.V.

Siberian State Medical University;
National Research Tomsk State University

Received:

08.06.2020

Accepted:

01.08.2020

Close metadata

References:

Stakhovskaya LV, Shamalov NA, Khasanova DR, Melnikova EV, Agafiina AS, Golikov KV, Bogdanov EI, Yakupova AA, Roshkovskay LV, Lukinykh LV, Lokshtanova TM, Poverennova IE, Shepankevich LA. Results of a randomized double blind multicenter placebo-controlled, in parallel groups trial of the efficacy and safety of prolonged sequential therapy with mexidol in the acute and early recovery stages of hemispheric ischemic stroke (EPICA). Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2017;(3-2):55-64. (In Russ.). https://doi.org/10.17116/jnevro20171173255-65
Lobzin VYu, Emelin AYu, Vorobyev SV, Lupanov IA. Current approaches to the diagnosis, prevention, and therapy of cognitive impairments in vascular encephalopathy. Neurology, Neuropsychiatry, Psychosomatics. 2014;(2):51-56. (In Russ.). https://doi.org/10.14412/2074-2711-2014-2-51-56
Antipenko EA, Derugina AV, Gustov AV. The system stress-limiting action of mexidol in chronic cerebral ischemia. Zhurnal Nevrologii i Psihiatrii imeni S.S. Korsakova. 2016;116(4):28-31. (In Russ.). https://doi.org/10.17116/jnevro20161164128-31
Solovieva EYu, Chipova DT. From the conception of «oxidizing stress» to the conception of «cell signaling modulation». Zhurnal Nevrologii i Psihiatrii imeni S.S. Korsakova. 2015;115(8):105-111. (In Russ.). https://doi.org/10.17116/jnevro201511581105-111
Voronina TA. The role of hypoxia in stroke and convulsive states. Antihypoxants. Reviews on Clinical Pharmacology and Drug Therapy. 2016;14(1):63-70. (In Russ.). https://doi.org/10.17816/RCF14163-70
Chukanova EI, Chukanova AS. Efficacy and safety of the drug mexidol FORTE 250 as part of sequential therapy in patients with chronic ischemia of the brain. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2019;119(9):39-45. (In Russ.). https://doi.org/10.17116/jnevro201911909139
Levin OS. Distsirculyatorny encephalopathy: anachronism or clinical reality. Sovremennaya Terapiya v Psichiatrii i Nevrologii. 2012;(3):40-46. (In Russ.).
Tinetti ME, Ginter SF. Identifying mobility dysfunction in elderly patients. Standart neuromuscular examination or direct assessment. JAMA. 1988;259:1190-1193.
Smets EMA, Garssen B, Bonke B, De Haes JC. The multidimensional fatigue inventory (MFI): psychometric qualities of an instrument to assess fatigue. J Psychosom Res. 1995;39:315-325.
Hamilton M. The assessment of anxiety states by rating. BR J Med Psychol. 1959;32(1):50-55. https://doi.org/10.1111/j.2044-8341.1959.tb00467.x
Hamilton M. A rating scale for depression. J Neurology Neurosurg Psychiat. 1960;23:56-62. https://doi.org/10.1136/jnnp.23.1.56
Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, Jeffrey L. The Monreal cognitive assessment, MoCa: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53:695-699. https://doi.org/10.1111/j.1532-5415.2005.53221.x
Guy W, ed. ECDEU assessment manual for psychopharmacology. Revised, 1976. DHEW Publication; 1976.
Narkevich IA, Zubov NN, Kuvakin VI. Statistika v biomeditsine, farmatsii i farmatsevtike. Moscow: KnoRus; 2019.